ERBB2 and breast cancer: In particular, approximately 40% of hormone-receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2–) breast cancers (BCs) exhibit aberrant activation of the PI3K pathway through gain-of-function mutations in the α isoform of PI3K.